Sandostatin LAR in acromegaly: A 6-week injection interval suppresses GH secretion as effectively as a 4-week interval

Clinical Endocrinology

Volumn 58, Issue 3, 2003, Pages 288-295

  Biermasz, Nienke R ^a   Van Den Oever, Niels C ^a   Frölich, Marijke ^a   Pereira Arias, Alberto M ^a   Smit, Jan W A ^a   Romijn, Johannes A ^a   Roelfsema, Ferdinand ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN BINDING PROTEIN 1;

ACROMEGALY; ARTICLE; BIOCHEMISTRY; BIOLOGICAL MONITORING; BLOOD SAMPLING; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; GROWTH HORMONE RELEASE; HORMONE BLOOD LEVEL; HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; REDUCTION; SCORING SYSTEM;

ACROMEGALY; ADULT; AGED; DELAYED-ACTION PREPARATIONS; DEPRESSION, CHEMICAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HORMONES; HUMANS; INJECTIONS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PROSPECTIVE STUDIES; SOMATOSTATIN;

EID: 0037335063     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2003.01710.x     Document Type: Article

References (40)

1. Abosch, A., Tyrrell, J.B., Lamborn, K.R., Hannegan, L.T., Applebury, C.B. & Wilson, C.B. (1998) Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. Journal of Clinical Endocrinology and Metabolism, 83, 3411-3418.
2. Ahmed, S., Elsheikh, M., Stratton, I.M., Page, R.C., Adams, C.B. & Wass, J.A. (1999) Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience. Clinical Endocrinology (Oxford), 50, 561-567.
3. Arosio, M., Macchelli, S., Rossi, C.M., Casati, G., Biella, O. & Faglia, G. (1995) Effects of treatment with octreotide in acromegalic patients - a multicenter Italian study. Italian Multicenter Octreotide Study Group. European Journal of Endocrinology, 133, 430-439.
4. Bates, A.S., Evans, A.J., Jones, P. & Clayton, R.N. (1995) Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-I and urinary growth hormone excretion. Clinical Endocrinology, 42, 417-423.
5. Bates, A.S., Van't Hoff, W., Jones, J.M. & Clayton, R.N. (1993) An audit of outcome of treatment in acromegaly. Quarterly Journal of Medicine, 86, 293-299.
6. Biermasz, N.R., van Dulken, H. & Roelfsema, F. (2000a) Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 85, 2476-2482.
7. Biermasz, N.R., van Dulken, H. & Roelfsema, F. (2000b) Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels. Clinical Endocrinology (Oxford), 53, 321-327.
8. Biermasz, N.R., van Dulken, H. & Roelfsema, F. (2000c) Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. Journal of Clinical Endocrinology and Metabolism, 85, 4596-4602.
9. Caron, P., Cogne, M., Gusthiot-Joudet, B., Wakim, S., Catus, F. & Bayard, F. (1995) Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). European Journal of Endocrinology, 132, 320-325.
10. Caron, P., Morange-Ramos, I., Cogne, M. & Jaquet, P. (1997) Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. Journal of Clinical Endocrinology and Metabolism, 82, 18-22.
11. Caron, P., Tabarin, A., Cogne, M., Chanson, P. & Jaquet, P. (2000) Variable growth hormone profiles following withdrawal of long-term 30 mg slow-release lanreotide treatment in acromegalic patients: clinical implications. European Journal of Endocrinology, 142, 565-571.
12. Chanson, P., Boerlin, V., Ajzenberg, C., Bachelot, Y., Benito, P., Bringer, J., Caron, P., Charbonnel, B., Cortet, C., Delemer, B., Escobar-Jimenez, F., Foubert, L., Gaztambide, S., Jockenhoevel, F., Kuhn, J.M., Leclere, J., Lorcy, Y., Perlemuter, L., Prestele, H., Roger, P., Rohmer, V., Santen, R., Sassolas, G., Scherbaum, W.A., Schopohl, J., Torres, E., Varela, C., Villamil, F. & Webb, S.M. (2000) Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clinical Endocrinology (Oxford), 53, 577-586.
13. Cozzi, R., Dallabonzana, D., Attanasio, R., Barausse, M. & Oppizzi, G. (1999) A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. European Journal of Endocrinology, 141, 267-271.
14. Erdman, R.A., Passchier, J., Kooijman, M. & Stronks, D.L. (1993) The Dutch version of the Nottingham Health Profile: investigations of psychometric aspects. Psychological Reports, 72, 1027-1035.
15. Ezzat, S., Snyder, P.J., Young, W.F., Boyajy, L.D., Newman, C., Klibanski, A., Molitch, M.E., Boyd, A.E., Sheeler, L. & Cook, D.M. (1992) Octreotide treatment of acromegaly. A randomized, multicenter study. Annals of Internal Medicine, 117, 711-718.
16. Flogstad, A.K., Halse, J., Bakke, S., Lancranjan, I., Marbach, P., Bruns, C. & Jervell, J. (1997) Sandostatin LAR in acromegalic patients: long-term treatment. Journal of Clinical Endocrinology and Metabolism, 82, 23-28.
17. Flogstad, A.K., Halse, J., Haldorsen, T., Lancranjan, I., Marbach, P., Bruns, C. & Jervell, J. (1995) Sandostatin LAR in acromegalic patients: a dose-range study. Journal of Clinical Endocrinology and Metabolism., 80, 3601-3607.
18. Gillis, J.C., Noble, S. & Goa, K.L. (1997) Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs, 53, 681-699.
19. Giustina, A., Barkan, A., Casanueva, F.F., Cavagnini, F., Frohman, L., Ho, K., Veldhuis, J., Wass, J., von Werder, K. & Melmed, S. (2000) Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism, 85, 526-529.
20. Grass, P., Marbach, P., Bruns, C. & Lancranjan, I. (1996) Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships. Metabolism, 45, 27-30.
21. Hunter, S.J., Shaw, J.A., Lee, K.O., Wood, P.J., Atkinson, A.B. & Bevan, J.S. (1999) Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion. Clinical Endocrinology (Oxford), 50, 245-251.
22. Jenkins, P.J., Akker, S., Chew, S.L., Besser, G.M., Monson, J.P. & Grossman, A.B. (2000) Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clinical Endocrinology (Oxford), 53, 719-724.
23. Kuhn, J.M., Arlot, S., Lefebvre, H., Caron, P., Cortet-Rudelli, C., Archambaud, F., Chanson, P., Tabarin, A., Goth, M.I., Blumberg, J., Catus, F., Ispas, S. & Beck-Peccoz, P. (2000) Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. Journal of Clinical Endocrinology and Metabolism, 85, 1487-1491.
24. Lancranjan, I. & Atkinson, A.B. (1999) Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. Pituitary, 1, 105-114.
25. Lancranjan, I., Bruns, C., Grass, P., Jaquet, P., Jervell, J., Kendall-Taylor, P., Lamberts, S.W., Marbach, P., Orskov, H., Pagani, G., Sheppard, M. & Simionescu, L. (1996) Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism, 45, 67-71.
26. van der Lely, A.J., Hutson, R.K., Trainer, P.J., Besser, G.M., Barkan, A.L., Katznelson, L., Klibanski, A., Herman-Bonert, V., Melmed, S., Vance, M.L., Freda, P.U., Stewart, P.M., Friend, K.E., Clemmons, D.R., Johannsson, G., Stavrou, S., Cook, D.M., Phillips, L.S., Strasburger, C.J., Hackett, S., Zib, K.A., Davis, R.J., Scarlett, J.A. & Thorner, M.O. (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet, 358, 1754-1759.
27. Lorcy, Y., Dejager, S. & Chanson, P. (2000) Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly. Pituitary, 3, 193-197.
28. Newman, C.B., Melmed, S., Snyder, P.J., Young, W.F., Boyajy, L.D., Levy, R., Stewart, W.N., Klibanski, A., Molitch, M.E. & Gagel, R.F. (1995) Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study. Journal of Clinical Endocrinology and Metabolism, 80, 2768-2775.
29. Orme, S.M., McNally, R.J., Cartwright, R.A. & Belchetz, P.E. (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism, 83, 2730-2734.
30. Parkinson, C., Renehan, A.G., Ryder, W.D., O'Dwyer, S.T., Shalet, S.M. & Trainer, P.J. (2002) Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly. Clinical Endocrinology (Oxford), 57, 59-64.
31. Powell, J.S., Wardlaw, S.L., Post, K.D. & Freda, P.U. (2000) Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure. Journal of Clinical Endocrinology and Metabolism, 85, 2068-2071.
32. Rajasoorya, C., Holdaway, I.M., Wrightson, P., Scott, D.J. & Ibbertson, H.K. (1994) Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology (Oxford), 41, 95-102.
33. Razzore, P., Colao, A., Baldelli, R., Gaia, D., Marzullo, P., Ferretti, E., Ferone, D., Jaffrain-Rea, M.L., Tamburrano, G., Lombardi, G., Camanni, F. & Ciccarelli, E. (1999) Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study. Clinical Endocrinology (Oxford), 51, 159-164.
34. Rosen, T., Wiren, L., Wilhelmsen, L., Wiklund, I. & Bengtsson, B.A. (1994) Decreased psychological well-being in adult patients with growth hormone deficiency. Clinical Endocrinology (Oxford), 40, 111-116.
35. Saveanu, A., Gunz, G., Dufour, H., Caron, P., Fina, F., Ouafik, L., Culler, M.D., Moreau, J.P., Enjalbert, A. & Jaquet, P. (2001) Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. Journal of Clinical Endocrinology and Metabolism, 86, 140-145.
36. Stewart, P.M., Stewart, S.E., Clark, P.M. & Sheppard, M.C. (1999) Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). Clinical Endocrinology (Oxford), 50, 295-299.
37. Swearingen, B., Barker, F.G., Katznelson, L., Biller, B.M., Grinspoon, S., Klibanski, A., Moayeri, N., Black, P.M. & Zervas, N.T. (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism., 83, 3419-3426.
38. Trainer, P.J., Drake, W.M., Katznelson, L., Freda, P.U., Herman-Bonert, V., van der Lely, A.J., Dimaraki, E.V., Stewart, P.M., Friend, K.E., Vance, M.L., Besser, G.M., Scarlett, J.A., Thorner, M.O., Parkinson, C., Klibanski, A., Powell, J.S., Barkan, A.L., Sheppard, M.C., Malsonado, M., Rose, D.R., Clemmons, D.R., Johannsson, G., Bengtsson, B.A., Stavrou, S., Kleinberg, D.L., Cook, D.M., Phillips, L.S., Bidlingmaier, M., Strasburger, C.J., Hackett, S., Zib, K., Bennett, W.F. & Davis, R.J. (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine, 342, 1171-1177.
39. Turner, H.E., Vadivale, A., Keenan, J. & Wass, J.A. (1999) A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clinical Endocrinology (Oxford), 51, 275-280.
40. Vance, M.L. & Harris, A.G. (1991) Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Archives of Internal Medicine, 151, 1573-1578.